In addition, in circumstances when a Unitholder receives, in connection with its investment in the Company, material
non-public
information concerning specific issuers, such Unitholder’s flexibility to buy or sell securities issued by such issuers or otherwise use such information may similarly be limited or restricted under applicable securities laws.
With respect to transactions involving material
non-public
information (among others), the Investment Committee may delegate investment and/or asset management decisions to other investment professionals of the Adviser in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee.
In the event any material,
non-public
information is disclosed to any person responsible for the affairs of the Company, the Company may be prohibited by applicable securities laws and the Company’s Joint Code of Ethics and Insider Trading Policy from acting upon any such information. Due to these restrictions, the Company may not be able to conclude a transaction that it otherwise might have concluded. In other cases, because of confidential or material
non-public
information acquired by SLR, the Company may also be prohibited from acquiring an investment that it otherwise might have acquired.
. With respect to a Portfolio Investment for which the Adviser determines
co-investment
capacity is available, the Adviser may, in its sole discretion, offer any portion of a
co-investment
to Unitholders or to third parties (which may be unaffiliated or affiliated with the Adviser or its affiliates, which may include Service Providers), or may cause the Company to retain such amounts. Each
co-investment
may be made by a separate vehicle formed for the purpose of making such
co-investment.
Any Unitholder participating in a
co-investment
may be required to pay fees (including management, incentive and administration fees) in connection with such
co-investment
(and, for the avoidance of doubt, any such fees or amounts shall not be considered Transaction Fees (as defined below). Distributions of income and proceeds related to each
co-investment
will be made separately from, and not aggregated with, distributions of income and proceeds related to the corresponding Portfolio Investment by the Company. “Transaction Fees” means the Company’s portion (as determined by the Company in its reasonable discretion) of any directors’, transaction,
break-up,
consulting, financial and advisory or other fees paid to the Adviser or any of its subsidiaries by any third party in connection with any proposed or existing Portfolio Investment; provided that, in each case, Transaction Fees will not include (i) any amounts paid as reimbursement for
expenses incurred in connection with providing services in respect of which such Transaction Fees were paid, (ii) any amounts paid to Service Providers in connection with any Company investment or (iii) any amounts paid by any investor or investment vehicle making a
co-investment
with the Company or investing alongside the Company. In determining the Company’s portion of any Transaction Fees, the Company may take into account its proportionate ownership of a Portfolio Investment’s entire capital structure (including both debt and equity). The Adviser or any of its subsidiaries may take actions to give effect to the above arrangement other than reducing Management Fees (
, rebating or waiving Transaction Fees at the Portfolio Investment level), in which case Transaction Fees will not reduce Management Fees as described above. For the avoidance of doubt, any fees and expenses paid to SLR Healthcare ABL (f/k/a Gemino Healthcare Finance LLC), or any existing or future entity which has been acquired by the Adviser or any affiliate of the Adviser, in each case, on an arms-length basis in connection with services provided in relation to any Portfolio Investments are not Transaction Fees and will not offset Management Fees.
The Adviser is under no obligation to provide
co-investment
opportunities to Unitholders, and any such
co-investment
opportunity may be offered to one or more third parties.
Co-investment
opportunities will be allocated as determined by the Adviser in its sole discretion. In determining such allocations, the Adviser may take into account any facts or circumstances it deems appropriate, including the size of the prospective
co-investor’s
investment in the Company and any other vehicles or accounts advised by the Adviser or its affiliates; whether and the extent to which the prospective
co-investor
has expressed an interest in
co-investment
opportunities; the Adviser’s evaluation of the financial resources, sophistication and experience of the potential
co-investor,
with respect to the execution of
co-investment
transactions generally, and with respect to the geographic location or business activities of the applicable Portfolio Investment; perception of past experiences and relationships with each prospective
co-investor;
whether or not such person has
co-invested
previously and the ability of any such
co-investor
to respond promptly and appropriately to potential investment opportunities; perception of the legal, regulatory, reporting, public relations, competitive, confidentiality or other issues that may arise with respect to any prospective
co-investor;
and any strategic value or other benefit to the Adviser or its affiliates resulting from offering such
co-investment
opportunity to a prospective
co-investor.
Nothing in this report constitutes a guarantee, prediction or projection of the availability of
co-investment
opportunities.
Co-investments
may result in conflicts between the Company and other
co-investors
(for example, over the price and other terms of such investment, exit strategies and related matters, including the exercise of remedies of their respective investments). Furthermore, to the extent that the Company holds interests that are different (or more senior) than those held by such other
co-investors,
the Adviser may be presented with decisions involving circumstances where the interests of such
co-investors
are in conflict with those of the Company. To the extent any affiliate of the Adviser
co-invests
with the Company, such conflicts will be heightened.